Immunotherapy combo tested for tough thyroid cancers
NCT ID NCT03753919
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 79 patients with advanced thyroid cancer that had progressed despite treatment. The goal was to see if the combination could slow or stop cancer growth. The study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and tremelimumab (immunotherapy drugs)
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced thyroid cancer that has stopped responding to standard therapies.
What could go wrong
The trial was terminated early, so results are limited. Immunotherapy can cause immune-related side effects, and the combination may not work for all thyroid cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clínica Universidad de Navarra
Pamplona, Spain
-
Complejo Hospitalario Universitario de Vigo (CHUVI)
Vigo, 36036, Spain
-
Hospital Clínic Barcelona
Barcelona, Spain
-
Hospital Clínico San Carlos
Madrid, Spain
-
Hospital General Universitario Morales Meseguer
Murcia, Spain
-
Hospital Provincial de Castellón
Castellon, Valencia, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitario La Paz
Madrid, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, Spain
-
Instituto Catalán de Oncología de Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Instituto Valenciano de Oncología
Valencia, 46009, Spain
-
MD Anderson Cancer Center
Madrid, 28033, Spain